ITM Raises €188m to Enhance Radiopharmaceutical Pipeline and to Strengthen Leading Position in Medical Radioisotope Manufacturing Proceeds to support development of ITM’s targeted radiopharmaceutical pipeline and preparations for potential market launch of phase III lead candidate, ITM-11, as it nears clinical read-out Funds...

ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177 Garching / Munich, Germany and Indianapolis, IN, USA, July 31, 2023 –  ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company and POINT Biopharma Global Inc. (NASDAQ:...

ITM eröffnet weltweit größte Anlage zur Produktion von Lutetium-177 für zielgerichtete Radionuklidtherapien gegen Krebs Neue Herstellungsanlage in Neufahrn bei München verzehnfacht ITMs Produktionskapazitäten Feierliche Eröffnung durch Staatsminister Dr. Florian Herrmann, Leiter der Bayerischen Staatskanzlei ...

ITM Opens World's Largest Lutetium-177 Production Facility for Targeted Radionuclide Therapies Against Cancer New manufacturing plant in Neufahrn near Munich increases ITM's production capacity tenfoldCeremonial opening by Minister of State, Dr. Florian Herrmann, Head of the Bavarian State Chancellery ...

ITM Announces €255m Investment Round, Plans to Advance Radiopharmaceutical Pipeline and to Expand Radioisotope Production Capacities  One of the largest private investment rounds in European biotech to-dateNet proceeds will enhance ITM’s radiopharmaceutical pipeline, bolster commercial infrastructure, expand leading...